AMX DATA
Financiado
Identification of risk factors for the development of colorectal cancer and / or premalignant lesions using Big Data tools and Artifical Intelligence for early cancer detection
Founded in 2010, AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people lives, develop...
Founded in 2010, AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear. The company’s products are oriented to non-invasive early cancer detection, avoiding the complications of existing invasive procedures, as tumor biopsies in colon, lung and pancreatic cancer. The application of Advanced Data Analytical tools in healthcare has a lot of positive and also life-saving potential. When speaking about data, we are referring to the vast quantities of information created in digitization of medical documents, and that could be consolidated and analyzed applying specific technologies. Aligned with our mission, AMADIX continues to go further, not only working at a molecular level but also exploring possibilities that clinical records and patient data offer (particular conditions, lifestyle, living area…). We are registering, processing and analyzing data through the latest Artificial Intelligence (AI) and Advanced Data Analytical Tools, in order to identify new risk factors, to develop predictive models which will help us anticipate hidden underlying cancer risk factors, treat patients in time and help improve the quality of life and survival of cancer patients. So, as an overview, the objective of AMX DATA is identifying risk factors in colon, lung and pancreatic cancer based on medical history, individual habits and image analysis to incorporate new risk cancer factors - in combination with our blood test gene signature - into our algorithms using Big Data tools and Artificial Intelligence.The development of this disruptive project requires the recruitment of an Innovation Associate with a multidisciplinary set of skills combining expertise and knowledge in cancer diagnostics and data analysis tools.
ver más
Duración del proyecto: 14 meses
Fecha Inicio: 2020-10-01
Fecha Fin: 2021-12-31
Fecha Fin: 2021-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-12-31
H2020
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Líder del proyecto
ADVANCED MARKER DISCOVERY
No se ha especificado una descripción o un objeto social para esta compañía.
